ClinicalTrials.gg
Enrolling by invitationNCT07691918MCIUpdated Nov 5, 2026

Mild Cognitive Impairment and Neuromodulation

An interventional study of Low intensity focused ultrasound and Sham (No Treatment) in Mild Cognitive Impairment (MCI), sponsored by Virginia Polytechnic Institute and State University. Enrolling by invitation at 1 site in United States. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Virginia Polytechnic Institute and State University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 5, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,423 studies in Cognitive Dysfunction with a site in United States — 330 open to participants now, 432 under way, 13 of them phase 3. Cognitive Dysfunction · United States.

Planned enrollment
692nd of 1,147
40 · median 59
Started
2026
with 96 others
No phase
716 of 1,423
182 open now
Primary completion
2028-07
later than 339 of 431 live
Registered
1,391st of 1,423
by date

Among the 1,423 studies in Cognitive Dysfunction with a site in United States, this one is the 692nd largest by planned enrollment of the 1,147 interventional ones that give a count, is one of 97 that started in 2026, is one of 716 with no phase, reaches primary completion later than 339 of the 431 other live ones, and was the 1,391st registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

330 of the 1,423 studies in Cognitive Dysfunction with a site in United States are open now. Recruiting first, the newest first:

325 more — sign in →

All 330 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 55 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,423 studies in Cognitive Dysfunction with a site in United States, or all of them as a file.
02

Study summary

This is a parallel, sham-controlled design of low-intensity focused ultrasound in patients with mild cognitive impairment (MCI). The study will evaluate safety, tolerability, and effects on cognitive function.

Read the detailed description

This parallel 2 arm study is sham controlled and collected over 6 study visits. Participants will receive MRI and CT scans, LIFU neuromodulation, cognitive assessments, and questionnaires batteries to assess tolerability and functional outcomes in an MCI population.

03

Conditions studied

  • Mild Cognitive Impairment (MCI)
04

Who can participate

Ages eligible
55 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (MoCA) scores between 18-23 inclusive, and able to consent to their own medical care.

Exclusion criteria

Exclusion Criteria:

  • Claustrophobia
  • MRI (pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, or other implants)
  • CT contraindications (pregnancy)
  • Non-AD etiology (eg. Lewy body disease, vascular dementia, alcohol/drug related damage)
  • Taking anti-amyloid antibodies
  • Neuromod within 6 months of the study
  • History of other neurological disorder
  • Hx of head injury with LOC > 10 min
  • Active alcohol or drug dependence
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Real LIFU

    Active Low Intensity Focused Ultrasound application

    Device: Low intensity focused ultrasound

  • Sham comparator
    Sham LIFU

    Blocked LIFU energy to the same brain region as the active group.

    Device: Sham (No Treatment)

Interventions

  • DeviceLow intensity focused ultrasound

    low-intensity focused ultrasound applied with a two element transducer from sonic concepts.

    Also known as: tFUS, FUS

  • DeviceSham (No Treatment)

    Blocked LIFU

06

What researchers measure

Primary outcomes

  1. Safety of LIFU in MCI patients - Report of Symptoms Assessment

    Symptom data (each possible symptom is listed \& scored on a likert scale - absent, mild, moderate, or severe. Free response section for any symptoms not listed.) collected before and during a follow-up period after LIFU application. Questionnaire data to be completed directly by the subject.

    Time frame: Throughout study participation - about 6 months in total.

  2. Tolerability Questionnaire Data

    Participants complete a questionnaire at the end of the study visit to query if they were uncomfortable/comfortable (on a likert scale, strongly disagree to strongly agree) during the experiment and if they would suggest the study to others. This data will be used to analyze tolerability of the study visits in this clinical population.

    Time frame: 30 minutes after the intervention

Secondary outcomes

  1. Effects on cognitive function using MoCA.

    The Montreal Cognitive Assessment (MoCA) will be performed at 4 time points throughout the participation in this study. This is used to assess any changes in cognitive processing - it evaluates memory, executive function, language, attention, and orientation. Assessment produces a score up to 30. 26 and above are considered cognitively normal. Between 19 and 25, a patient is considered to have mild cognitive impairment.

    Time frame: 4 times over the course of study participation - which is about 6 months in total.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2028, 19 months later.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 19 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jul 9, 2026
StartEst.
Dec 2026was Oct 2026
Primary completionEst.
Jul 2028
CompletionEst.
Dec 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Dec 2026
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Start date Oct 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07691918
Responsible party
Wynn Legon (Assistant Professor, Virginia Polytechnic Institute and State University) — Principal investigator
First posted
Jul 9, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jul 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion